The Technical AnalystExchange: EURONEXT Industry: Biotechnology
Erytech Pharma SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.25% €0.801
America/New_York / 28 jun 2023 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 48.66 mill |
| EPS: | -0.0100 |
| P/E: | -80.10 |
| Earnings Date: | Sep 11, 2023 |
| SharesOutstanding: | 60.75 mill |
| Avg Daily Volume: | 0.215 mill |
| RATING 2023-06-28 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | |||||
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -80.10 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -80.10 | industry: PE -7.48 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 0.737 - 0.865 ( +/- 7.99%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €0.801 (0.25% ) |
| Volume | 0.0275 mill |
| Avg. Vol. | 0.215 mill |
| % of Avg. Vol | 12.78 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ERYP.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ERYP.PA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.